Patients with severe eosinophilic asthma, prior biologic use benefit from benralizumab
Among adults with severe eosinophilic asthma and previous biologic use, benralizumab for 48 weeks aided in reducing exacerbations and improving asthma symptom control, according to results published in European Respiratory Journal.These outcomes were also found among adults with severe eosinophilic asthma and no previous biologic use, according to researchers.